Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
CTA vs IBB: how they differ
CTA and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
Simplify Managed Futures Strategy ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, CTA and IBB hold 0% of their money in the same securities at the same weight.
| Only in CTA | Only in IBB |
|---|---|
| SIMPLIFY EXCHANGE TRADED FUNDS 81.69% | Vertex Pharmaceuticals, Inc. 8.09% |
| UNITED STATES OF AMERICA - BUREAU OF THE 3.72% | Amgen, Inc. 7.84% |
| UNITED STATES OF AMERICA - BUREAU OF THE 3.44% | Gilead Sciences, Inc. 6.85% |
| UNITED STATES OF AMERICA - BUREAU OF THE 2.76% | Regeneron Pharmaceuticals, Inc. 4.91% |
| UNITED STATES OF AMERICA - BUREAU OF THE 2.75% | Argenx SE 3.76% |
| UNITED STATES OF AMERICA - BUREAU OF THE 2.20% | Alnylam Pharmaceuticals, Inc. 3.12% |
| UNITED STATES OF AMERICA - BUREAU OF THE 1.37% | Natera, Inc. 2.89% |
| UNITED STATES OF AMERICA - BUREAU OF THE 1.07% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| CTA Simplify Managed Futures Strategy ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Simplify | iShares |
| What it is | Simplify Managed Futures Strategy | Biotechnology |
| Total return, 1 year | +17.0% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −0.5 pts | +24.0 pts |
| Expense ratio | 0.75% | 0.44% |
| Already in the S&P 500 | 0.0% | 35.6% |
| Holdings | 10 | 248 |
CTA in plain words
CTA is an index equity fund tracking the Simplify Managed Futures Strategy. Over the year to Sep 11, 2026 it returned +17.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.75% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 10 positions, with the top ten at 100.0%. It sat 5.3% below its high of May 4, 2026 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, CTA or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, CTA returned +17.0% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, CTA or IBB?
- CTA charges 0.75% a year and IBB charges 0.44%, so IBB is cheaper. Fees come from each fund's prospectus.
- How much do CTA and IBB overlap with the S&P 500?
- By their latest filed holdings, 0% of CTA and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CTA against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/CTA-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources